This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Pubmed/NCBI databases Substance via MeSH Related Collections Coagulation and fibronolysis Other Treatment Anticoagulant mechanisms

(Circulation. 2000;102:2726.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity

A Phase II Evaluation

The Rembrandt Investigators¹

Correspondence to H.R. Büller, Academic Medical Centre, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands. E-mail m.m.veendorp{at}amc.uva.nl

Background—Patients with venous thromboembolism require initial treatment with an immediate-acting anticoagulant, low-molecular-weight heparin. We evaluated a novel synthetic factor Xa inhibitor (SR90107a/ORG31540) as an alternative treatment.

Methods and Results—A randomized-parallel-group, phase II trial to assess the efficacy and safety of SR90107a/ORG31540 (5, 7.5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, 100 IU/kg twice daily) in symptomatic proximal deep vein thrombosis. The primary outcome measure was the change in thrombus mass, assessed by ultrasonography of the leg veins and perfusion lung scintigraphy, performed at baseline and day 7±1. A positive outcome was defined as improvement of the ultrasound and/or perfusion scan result without deterioration of either test. Other outcome measures included symptomatic, recurrent venous thromboembolism and major bleeding for a period of 3 months. All outcomes were interpreted with the observer unaware of treatment allocation. A positive primary outcome was observed in 46 of 100 (46%), 52 of 108 (48%), 48 of 115 (42%), and 56 of 115 (49%), respectively, of the subjects given 5, 7.5, or 10 mg SR90107a/ORG31540 or dalteparin. There were 8 recurrent thromboembolic complications (2.4%) in the 334 patients treated with SR90107a/ORG31540 and 6 (5.0%) in the 119 dalteparin patients, a difference of 2.6% in favor of SR90107a/ORG31540 (95% CI -2.1% to 10.1%). The incidence of bleeding was low and was similar among the groups.

Conclusions—The factor Xa inhibitor SR90107a/ORG31540 appears to be an effective and safe treatment for patients with deep vein thrombosis across a wide range of doses. This synthetic compound merits evaluation in phase III studies.

Key Words: anticoagulants • heparin • imaging • thrombosis

This article has been cited by other articles:

				A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF]

				G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong, and for the ODIXa-DVT Study Investigators Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study Circulation, July 10, 2007; 116(2): 180 - 187. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom and J. I. Weitz A Replacement for Warfarin: The Search Continues Circulation, July 10, 2007; 116(2): 131 - 133. [Full Text] [PDF]

				K. A. Bauer New Anticoagulants Hematology, January 1, 2006; 2006(1): 450 - 456. [Abstract] [Full Text] [PDF]

				P. Savi, B. H. Chong, A. Greinacher, Y. Gruel, J. G. Kelton, T. E. Warkentin, P. Eichler, D. Meuleman, M. Petitou, J.-P. Herault, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin Blood, January 1, 2005; 105(1): 139 - 144. [Abstract] [Full Text] [PDF]

				M. McGuire and P. P. Dobesh Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 289 - 307. [Abstract] [PDF]

				H. R. Buller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 401S - 428S. [Abstract] [Full Text] [PDF]

				H. R. Buller, B. L. Davidson, H. Decousus, A. Gallus, M. Gent, F. Piovella, M. H. Prins, G. Raskob, A. E.M. Segers, R. Cariou, et al. Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial Ann Intern Med, June 1, 2004; 140(11): 867 - 873. [Abstract] [Full Text] [PDF]

				V. Pengo, A. W.A. Lensing, M. H. Prins, A. Marchiori, B. L. Davidson, F. Tiozzo, P. Albanese, A. Biasiolo, C. Pegoraro, S. Iliceto, et al. Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism N. Engl. J. Med., May 27, 2004; 350(22): 2257 - 2264. [Abstract] [Full Text] [PDF]

				J. Lorrain, I. Lechaire, C. Gauffeny, R. Masson, N. Roome, J.-P. Herault, S. E. O'Connor, P. Schaeffer, and J.-M. Herbert Effects of SanOrg123781A, a Synthetic Hexadecasaccharide, in a Mouse Model of Electrically Induced Carotid Artery Injury: Synergism with the Antiplatelet Agent Clopidogrel J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 235 - 240. [Abstract] [Full Text]

				L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]

				K. A. Bauer New Pentasaccharides for Prophylaxis of Deep Vein Thrombosis: Pharmacology Chest, December 1, 2003; 124(6_suppl): 364S - 370S. [Abstract] [Full Text] [PDF]

				A. G. G. Turpie, B. I. Eriksson, K. A. Bauer, and M. R. Lassen New Pentasaccharides for the Prophylaxis of Venous Thromboembolism: Clinical Studies Chest, December 1, 2003; 124(6_suppl): 371S - 378S. [Abstract] [Full Text] [PDF]

				A. H Tran and G. Lee Fondaparinux for Prevention of Venous Thromboembolism in Major Orthopedic Surgery Ann. Pharmacother., November 1, 2003; 37(11): 1632 - 1643. [Abstract] [Full Text] [PDF]

				The Matisse Investigators Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism N. Engl. J. Med., October 30, 2003; 349(18): 1695 - 1702. [Abstract] [Full Text] [PDF]

				T. M. Hyers Management of Venous Thromboembolism: Past, Present, and Future Arch Intern Med, April 14, 2003; 163(7): 759 - 768. [Abstract] [Full Text] [PDF]

				E. Kalodiki and A. N. Nicolaides Superficial Thrombophlebitis and Low-Molecular-Weight Heparins Angiology, November 1, 2002; 53(6): 659 - 663. [Abstract] [PDF]

				C. K. Dyke, R. C. Becker, N. S. Kleiman, J. S. Hochman, E. G. Bovill, A. M. Lincoff, G. Gerstenblith, V. Dzavik, L. H. Gardner, V. Hasselblad, et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation Circulation, May 21, 2002; 105(20): 2385 - 2391. [Abstract] [Full Text] [PDF]

				N. S. Quinsey, J. C. Whisstock, B. Le Bonniec, V. Louvain, S. P. Bottomley, and R. N. Pike Molecular Determinants of the Mechanism Underlying Acceleration of the Interaction between Antithrombin and Factor Xa by Heparin Pentasaccharide J. Biol. Chem., May 3, 2002; 277(18): 15971 - 15978. [Abstract] [Full Text] [PDF]